Skip to main content

Table 4 Pregnancy rate and OHSS rate for hMG versus r-hFSH

From: Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis

Studied endpoint for hMG versus r-hFSH RR 95% CI p value RD 95% CI P value
Pregnancy rate       
   - Main analysis 1.10 0.97, 1.25 0.06 0.03 -0.01, 0.07 0.051
   - Sub-group 1 1.09 0.95, 1.24 0.10 0.03 -0.01, 0.07 0.08
   - Sub-group 2 1.09 0.95, 1.26 0.12 0.03 -0.01, 0.07 0.08
Pregnancy rate adjusted for baseline 1.04 0.89, 1.15 0.49 0.01 -0.02, 0.04 0.34
OHSS       
   - Main analysis 1.47 0.91, 2.39 0.12 0.02 -0.00, 0.04 0.72
   - Sub-group 1 1.40 0.84, 2.36 0.20 0.01 -0.00, 0.03 0.65
   - Sub-group 2 1.40 0.84, 2.34 0.20 0.01 -0.00, 0.03 0.62
  1. hMG = human menopausal gonadotrophins; r-hFSH = recombinant human follicle-stimulating hormone; OHSS = ovarian hyperstimulation syndrome; RR = relative risk; RD = absolute risk difference